Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
about
Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?Oral nonsteroidal anti-inflammatory drugs for neuropathic painOral nonsteroidal anti-inflammatory drugs for neuropathic painA turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicityTime dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approachDietary antioxidants protect gut epithelial cells from oxidant-induced apoptosisRole of Chlorogenic Acids in Controlling Oxidative and Inflammatory Stress ConditionsEsomeprazole and aspirin fixed combination for the prevention of cardiovascular eventsNon-microbial approach for Helicobacter pylori as faster track to prevent gastric cancer than simple eradicationSynthesis and Functions of Jasmonates in MaizeRole of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug usersDelay in oral mucosal ulcer healing by aspirin is linked to the disturbances in p38 mitogen-activated protein kinase activationPractical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDsBalancing the gastrointestinal benefits and risks of nonselective NSAIDs.Peptic ulcer disease todaySafety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring studyTreatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleedingReview article: gastrointestinal bleeding with low-dose aspirin - what's the risk?Analysis of aspirin-associated risks in healthy individualsUse of antisecretory drugs among consumers of non-steroidal anti-inflammatory drugs in the general populationThe impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitorPrimary prevention of cardiovascular disease: cost-effectiveness comparisonAn economic model of long-term use of celecoxib in patients with osteoarthritisClinical Pharmacology and Cardiovascular Safety of NaproxenGI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trialA 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.Effect of aspirin cessation before endoscopy in Japanese patients with low-dose-aspirin-associated gastroduodenal mucosal injuryCampania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug ReactionsPharmaceutical company influence on nonsteroidal anti-inflammatory drug prescribing behaviors.Effects of chronic therapy with non-steroidal antiinflammatory drugs on gastric permeability of sucrose: a study on 71 patients with rheumatoid arthritis.Novel Actions of Nonsteroidal Anti-Inflammatory Drugs on Vascular Ion Channels: Accounting for Cardiovascular Side Effects and Identifying New Therapeutic Applications.The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy.Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirinPharmacologic management of osteoarthritis-related pain in older adults.Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review.Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis.Myocardial Infarction and Its Association with the Use of Nonselective NSAIDs: A Nested Case-Control and Time-to-Event Analysis.Development and validation of a sensitive and high-throughput LC-MS/MS method for the simultaneous determination of esomeprazole and naproxen in human plasma.Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers.
P2860
Q22306448-3722B8CF-AF7E-42B3-9700-BE95133ADB44Q24186621-DD1206E2-5B43-43A6-AC0F-D633E9069127Q24202080-82B5A94A-1BA3-4AB0-B5E1-17631633C8CFQ24615651-4BA1B3AC-AA53-41BF-9D06-B30334B3B5F3Q24673561-80F761FC-B747-4B4F-85DF-875DD6D23369Q24797247-C7C9226B-3FE3-440A-87EA-98621B171BC5Q26771798-2D41A3BA-6097-47B1-BB6C-CE18CF87936EQ26995752-49F6C12E-0FF0-4ACA-ADB6-D8C50D49C384Q27006833-B41D07E4-5C9F-47E9-B0A2-84C92DA06FC3Q28079099-5B2F34EA-0963-48FB-A644-90444E423915Q28182449-86935C9C-080A-4722-A7D7-C199C08AE26BQ28186400-B31BFC66-9914-4C3F-AC6E-2104783495E7Q28191928-73910BBD-2FDF-4082-8022-9A4D25CDE643Q28191932-310C8DA1-295E-49A4-B968-D702D9E73D38Q28194844-499771D4-0A0C-43FC-A049-EE4522AA591CQ28194919-A9BE9C3E-73F3-4D82-9E63-EEC83D453B3EQ28198718-11347D31-2ED0-41A5-9495-C3926DA7DC82Q28200403-654434F7-C599-4229-B663-3BC15F24CAA0Q28211608-D5C11B07-86BE-4772-9F6B-3F84571DF31AQ28213904-2CFFAA2E-7518-40CA-95EB-086D63F823DBQ28217400-73F9A9C3-E17B-4936-AAA5-9F518830BC96Q28217877-810DAB94-5785-49DB-BA70-E631C69F4EDCQ28218005-528B21C2-9F1A-447F-A7F1-56B3017B54F8Q30360728-883021B5-04F5-4877-8430-7E4B9AD3BFE4Q30537237-771DE368-105B-4AED-8B54-730454348BFEQ33367787-B8A970FC-83F4-4F95-864D-113853DA6C40Q33695564-53D1CBE4-512B-40A8-9630-10508E8419FDQ33729501-0A395855-4BF3-46E6-B195-96EAE6EA2323Q33814067-F0C2E0ED-F7C0-4B45-8A9D-A0F85D94F945Q33866162-E9514672-8B05-450D-B3E1-EB3C323CC7F7Q34043009-6B4843BC-21B6-4F49-8A12-7F8C42878EDFQ34161152-1FCEC759-E0D7-439F-9E37-F6B18CE44CCDQ34177563-452C5874-9C76-40A3-AA7B-704A71B62D87Q34257433-9536221E-5192-4A64-B974-571F15FF41E8Q34384075-7A68DA15-7467-4DE0-B13A-CC7CCCFB5742Q34449825-76A0C6F8-27EB-4B3B-B0CF-48C82FF05CB2Q34499039-E53EB118-36BE-4D85-9941-20E02A5FCAE1Q34589334-2A706A0D-514B-4BD3-BFB8-202DDFE233F0Q34618109-CE1D3334-1B4B-4A10-A20F-5BE7C054BC66Q35038558-F8B73428-41F7-46D5-9704-1C459BBFF4F1
P2860
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
@ast
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
@en
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
@nl
type
label
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
@ast
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
@en
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
@nl
prefLabel
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
@ast
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
@en
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
@nl
P356
P1433
P1476
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
@en
P2093
P304
P356
10.1053/GAST.2001.21907
P407
P577
2001-02-01T00:00:00Z